Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Ensysce Biosciences ( (ENSC) ).
On April 6, 2026, Ensysce Biosciences closed a $2 million private offering under a 2025 securities purchase agreement, issuing Series B preferred stock convertible at $0.55 per share and accompanying warrants for up to 8,727,273 common shares, alongside additional advisor warrants. The financing, announced on April 7, 2026, provides roughly $1.9 million in net proceeds to help maintain the company’s flagship TAAP and MPAR pain programs and support working capital, while reinforcing investor backing for its strategy to advance abuse- and overdose-resistant analgesics.
The transaction tightens Ensysce’s capital structure through anti-dilution protections and warrant and conversion price adjustments linked to future equity issuance, while imposing limits on additional variable-rate financings as long as the investor holds a specified amount of preferred stock. By drawing a second tranche from a committed funding line of up to $20 million over 24 months, the company shores up near-term liquidity for its clinical pipeline without a public equity sale, though the structure implies potential future dilution for common shareholders as preferred shares convert and warrants are exercised.
The most recent analyst rating on (ENSC) stock is a Hold with a $0.58 price target. To see the full list of analyst forecasts on Ensysce Biosciences stock, see the ENSC Stock Forecast page.
Spark’s Take on ENSC Stock
According to Spark, TipRanks’ AI Analyst, ENSC is a Neutral.
The score is primarily held down by weak financial performance—collapsed revenue, persistent large losses, and sustained cash burn—despite some balance sheet improvement. Technicals provide only modest support (short-term strength but weak longer-term trend), while valuation offers limited help given an uninformative P/E and no dividend. Corporate events are mixed, balancing governance turnover against approvals that increase capital flexibility.
To see Spark’s full report on ENSC stock, click here.
More about Ensysce Biosciences
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of highly novel opioid analgesics for severe pain. Using its proprietary TAAP and MPAR platforms, the company aims to deliver tamper-resistant pain treatments designed to reduce abuse and overdose risk, supported by a global intellectual property portfolio.
Average Trading Volume: 6,211,342
Technical Sentiment Signal: Sell
Current Market Cap: $5.34M
See more insights into ENSC stock on TipRanks’ Stock Analysis page.